BREITMEYER JAMES B
BREITMEYER JAMES B is a corporate insider at CADENCE PHARMACEUTICALS INC (CADX) filing SEC Form 4 transactions. 168 transactions across 5 companies, totaling $86,010 in purchases and $1,539,088 in sales. Source: SEC EDGAR.
The smallest detail that reveals James B. Breitmeyer's present strategy is a ticker that barely appears in the sell ledger: Vaxart (VXRT) shows 4 transactions with 0 buy and 0 sell shares — yet the entire recent 2026 Form 4 window is VXRT awards (16,610 and 8,315 shares on 2026-07-16; 157,400 and 78,800 on 2026-04-23). Zoom to the career totals across 168 filings and the distribution history lives elsewhere: Oncternal Therapeutics (64 filings; 175,000 buy vs 2,737,697 sell), Cadence Pharmaceuticals (68 filings; 0 buy / 127,500 sell), and Zogenix (23 filings; 0 buy / 86,625 sell). Otonomy and Applied Molecular Evolution are award-only stubs. The strategy today is new biotech board equity landing at VXRT; the multi-million-share sell total is an Oncternal-era legacy.
Companies
Transaction History
Source: SEC EDGAR Form 4 insider transaction filings.
Company | Type | Shares | Price | Value | Shares After | Date | SEC |
|---|---|---|---|---|---|---|---|
Vaxart, Inc. VXRT | Award | 16,610 | $0.51 | $9K | 16,610 | 7/16/2026 Filed: 7/16/2026 | Filing → |
Vaxart, Inc. VXRT | Award | 8,315 | - | - | 87,115 | 7/16/2026 Filed: 7/16/2026 | Filing → |
Vaxart, Inc. VXRT | Award | 157,400 | $0.74 | $116K | 157,400 | 4/23/2026 Filed: 4/23/2026 | Filing → |
Vaxart, Inc. VXRT | Award | 78,800 | - | - | 78,800 | 4/23/2026 Filed: 4/23/2026 | Filing → |
Oncternal Therapeutics, Inc. ONCT | Award | 6,200 | - | - | 6,200 | 2/14/2024 Filed: 2/15/2024 | Filing → |
Oncternal Therapeutics, Inc. ONCT | Award | 28,400 | - | - | 28,400 | 2/14/2024 Filed: 2/15/2024 | Filing → |
Oncternal Therapeutics, Inc. ONCT | Tax Payment | 4,485 | $0.50 | $2K | 15,426 | 1/3/2024 Filed: 1/5/2024 | Filing → |
Oncternal Therapeutics, Inc. ONCT | Tax Payment | 50,955 | $0.50 | $25K | 443,034 | 1/3/2024 Filed: 1/5/2024 | Filing → |
Oncternal Therapeutics, Inc. ONCT | Award | 65,000 | - | - | 65,000 | 10/2/2023 Filed: 10/4/2023 | Filing → |
Oncternal Therapeutics, Inc. ONCT | Award | 12,500 | - | - | 12,500 | 10/2/2023 Filed: 10/4/2023 | Filing → |
Oncternal Therapeutics, Inc. ONCT | Award | 165,000 | - | - | 165,000 | 10/2/2023 Filed: 10/4/2023 | Filing → |
Oncternal Therapeutics, Inc. ONCT | Award | 2,000 | - | - | 2,000 | 10/2/2023 Filed: 10/4/2023 | Filing → |
Oncternal Therapeutics, Inc. ONCT | Award | 7,000 | - | - | 7,000 | 10/2/2023 Filed: 10/4/2023 | Filing → |
Oncternal Therapeutics, Inc. ONCT | Award | 22,000 | - | - | 12,240 | 10/2/2023 Filed: 10/4/2023 | Filing → |
Oncternal Therapeutics, Inc. ONCT | Disposition | 65,000 | - | - | 0 | 10/2/2023 Filed: 10/4/2023 | Filing → |
Oncternal Therapeutics, Inc. ONCT | Disposition | 12,500 | - | - | 0 | 10/2/2023 Filed: 10/4/2023 | Filing → |
Oncternal Therapeutics, Inc. ONCT | Disposition | 165,000 | - | - | 0 | 10/2/2023 Filed: 10/4/2023 | Filing → |
Oncternal Therapeutics, Inc. ONCT | Disposition | 2,000 | - | - | 0 | 10/2/2023 Filed: 10/4/2023 | Filing → |
Oncternal Therapeutics, Inc. ONCT | Disposition | 7,000 | - | - | 0 | 10/2/2023 Filed: 10/4/2023 | Filing → |
Oncternal Therapeutics, Inc. ONCT | Disposition | 22,000 | - | - | 0 | 10/2/2023 Filed: 10/4/2023 | Filing → |
Try asking...